What's the largest size tumor you would do SBRT of the lung for? It's a peripheral nodule close to the ribs. What dose would you use for large lesions?
I think anything up to 7cm is somewhat fair game, depending on situation, constraints, etc. It may get dicey close to 7cm. I don't necessarily agree with the reasoning of giving concurrent chemoradiation for the purpose of it treating systemic micromets. The concurrent chemoradiation trials tend to suggest that the benefit is mostly locally anyways.
My take is that SBRT probably still gives better local control if feasible. If you are concerned about systemic failure, give them neoadjuvant or adjuvant chemo, more like a surgical paradigm.
the problem is, safety of chemo after SBRT has not been established
Agree with that. Just like in H&N, the chemo dosing isn't going really have a lot of distant effects, it's really just for radiosenitization (obvious in the larynx preservation trials). I do think control with even SBRT takes a hit somewhere above 5 cm, just not sure where. In a world of unlimited funding and patients that could be accrued to trials, would love to see an RCT of T2b/T3N0 pts getting SBRT vs chemoradiation.I think anything up to 7cm is somewhat fair game, depending on situation, constraints, etc. It may get dicey close to 7cm. I don't necessarily agree with the reasoning of giving concurrent chemoradiation for the purpose of it treating systemic micromets. The concurrent chemoradiation trials tend to suggest that the benefit is mostly locally anyways.
My take is that SBRT probably still gives better local control if feasible. If you are concerned about systemic failure, give them neoadjuvant or adjuvant chemo, more like a surgical paradigm.
Except Carbo/taxol with consolidation is not the preferred regimen in medically fit patients (despite the prevalence in the U.S.and rtog) and you typically don't consolidate a cis-based regimen.I would strongly disagree with above.
a) Full dose pac/carbo (usually given as consolidation for 2-3 q3 weekly cycles after weekly concomitant pac/carbo) improves overall survival by treating micrometastases. That is evident from adjuvant chemo trials after surgery.
b) Pac/carbo increases probability of radiation pneumonitis. That's true in post-SBRT setting until proven otherwise. My MedOnc would not give chemo after SBRT due to that.
Therefore, for a 5 cm peripheral NSCLC, chemo-rads to 66 Gy/33 fx is superior to SBRT. For centrally located tumors, it's a no-brainer.
I would strongly disagree with above.
a) Full dose pac/carbo (usually given as consolidation for 2-3 q3 weekly cycles after weekly concomitant pac/carbo) improves overall survival by treating micrometastases. That is evident from adjuvant chemo trials after surgery.
b) Pac/carbo increases probability of radiation pneumonitis. That's true in post-SBRT setting until proven otherwise. My MedOnc would not give chemo after SBRT due to that.
Therefore, for a 5 cm peripheral NSCLC, chemo-rads to 66 Gy/33 fx is superior to SBRT. For centrally located tumors, it's a no-brainer.
http://www.ncbi.nlm.nih.gov/pubmed/22682812What is this a Med Onc Forum?! All this talk about carbo/taxol, cisplatin.. Heh.. Just kidding. Actually.. can you forward some of the data on b) that Pac/Carbo increases radiation pneumonitis.. actually interested in that regarding a project...
Probably less studied, most ppl do concurrent in stage IIIA, unless pt can only tolerate sequential.Unless I'm mistaken, this data is for concurrent only. Do we have the studies for adjuvant or neoadjuvant chemo causing pneumonitis?
This point seems questionable when we are talking about post XRT versus concurrentI would strongly disagree with above.
...
b) Pac/carbo increases probability of radiation pneumonitis. That's true in post-SBRT setting until proven otherwise. My MedOnc would not give chemo after SBRT due to that.
....
I would strongly disagree with above.
a) Full dose pac/carbo (usually given as consolidation for 2-3 q3 weekly cycles after weekly concomitant pac/carbo) improves overall survival by treating micrometastases. That is evident from adjuvant chemo trials after surgery.
b) Pac/carbo increases probability of radiation pneumonitis. That's true in post-SBRT setting until proven otherwise. My MedOnc would not give chemo after SBRT due to that.
Therefore, for a 5 cm peripheral NSCLC, chemo-rads to 66 Gy/33 fx is superior to SBRT. For centrally located tumors, it's a no-brainer.
http://www.biomedcentral.com/content/pdf/1748-717X-6-24.pdfRecall pneumonitis is possible with taxanes
I think there is a benefit in large tumors. There is good data for chemo rt in stage IIIA/B patients which includes some large t3 tumors in it. Where I trained, our chairman was a big lung guy and he felt that the really large tumors probably did better with chemo-rt maybe with a little hypofx rather than sbrt alone.I dunno man - isn't that chemo data for >4cm pretty weak? I can't say I would subject a patient to chemoRT based on size, not unless they were N+. Why not treat with SBRT up front and reserve chemo for salvage if they fail?
Am I an island in that thinking?
Yes although the cytology can be low yield. If the pt keeps on recurring with effusions, prob malignantWould you send the guy to get drained?
Yes although the cytology can be low yield. If the pt keeps on recurring with effusions, prob malignant
Anythings possible. Adeno's can do it. Worth draining imo and proceeding onIts just a T1a though? It is weird that it is unilateral don't get me wrong but really, malignant effusion in a T1a? I don't see anything else suspicious by PET?